Innovent Biologics, Inc.
OTC: IVBXF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- De-Chao Yu
- Employees
- 5,659
- Headquarters
- Suzhou, China
- IPO year
- 2019
- Market cap
- $17.8B
- Website
- https://www.innoventbio.com
Loading IVBXF…
Loading profile data…Frequently asked questions about IVBXF
What does Innovent Biologics, Inc. (IVBXF) do?
Innovent Biologics, Inc. is a biopharmaceutical firm headquartered in Suzhou, People's Republic of China, established in 2011. It specializes in the discovery, advancement, and production of antibody-based drug candidates, with a strategic focus on therapeutic areas including cancer treatment (oncology), eye conditions (ophthalmology), immune sy...
Where does IVBXF trade?
Innovent Biologics, Inc. (IVBXF) trades on the Other OTC.
What sector is IVBXF in?
Innovent Biologics, Inc. (IVBXF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Innovent Biologics, Inc.?
De-Chao Yu is the chief executive officer of Innovent Biologics, Inc. (IVBXF).
Where is Innovent Biologics, Inc. headquartered?
Innovent Biologics, Inc. is headquartered in China.
Does IVBXF pay a dividend?
Innovent Biologics, Inc. (IVBXF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did IVBXF go public?
Innovent Biologics, Inc. (IVBXF) completed its initial public offering in 2019.